Thrombopoietin receptor agonists in the treatment of thrombocytopenia

Current Opinion in Hematology

Volumn 16, Issue 5, 2009, Pages 357-364

  Newland, Adrian ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AMG 531; Eltrombopag; Immune thrombocytopenia; Platelet response; Romiplostim; Thrombopoietin

Indexed keywords

AKR 501; ELTROMBOPAG; NAPHTHALENESULFONIC ACID DERIVATIVE; PLACEBO; RETICULIN; ROMIPLOSTIM;

ARTERY EMBOLISM; BLEEDING; CLINICAL TRIAL; DISEASE DURATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BENZOIC ACIDS; CARRIER PROTEINS; HUMANS; HYDRAZINES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOPENIA;

EID: 69549130802     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32832e06e4     Document Type: Review

References (52)

1. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94:909-913. (Pubitemid 29361821)
2. Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122:966-974.
3. Schoonen M, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Brit J Haematol 2009; 145:235-244.
4. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78 (6 Suppl 2):35-40.
5. Stasi R, Stipa E, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98:436-442.
6. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3-40.
7. Vianelli N, Valdre L, Fiacchini M, et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica 2001; 86:504-509. (Pubitemid 33638979)
8. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97:2549-2554.
9. Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol 2002; 118:933-944. (Pubitemid 35025954)
10. Provan D, Newland AC, Norfolk D, et al. British Committee for Standards in Haematology, General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120:574-596.
11. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113:1231-1240.
12. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104:2623-2634. (Pubitemid 39434940)
13. Arnold D, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146:25-33. (Pubitemid 351650318)
14. Cooper N, Evangelista ML. Should rituximab be used before or after splenectomy in patients with idiopathic thrombocytopenic purpura? Curr Opin Hematol 2007; 14:642-646.
15. Psaila B, Bussel J. Refractory idiopathic thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 2008; 143:16-26. A review of the treatment options in refractory ITP highlighting the potential role of the thrombopoietin agonists.
16. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995-1008.
17. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103:1364-1369. (Pubitemid 38168649)
18. Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103:500-506.
19. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenic purpura: increased platelet destruction and/or ineffective platelet production. Br J Haematol 2009 [Epub ahead of print].
20. Odell TT Jr, Mc DT, Detwiler TC. Stimulation of platelet production by serum of platelet-depleted rats. Proc Soc Exp Biol Med 1961; 108:428-431.
21. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77:1117-1124. (Pubitemid 124000761)
22. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369:533-538. (Pubitemid 24192520)
23. Vainchenker W, Methia N, Debili N, et al. c-mpl, the thrombopoietin receptor. Thromb Haemost 1995; 74:526-528.
24. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109:4607-4616.
25. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100:3457-3469. (Pubitemid 35303910)
26. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-3248.
27. Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol 2007; 44:35-45. (Pubitemid 350256801)
28. Nogami W, Yoshida H, Koizumi K, et al. The effect of a novel small nonpeptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Hematologica 2008; 93:1495-1504.
29. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87:4068-4071.
30. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93:704-706. (Pubitemid 26167375)
31. Nichol JL. Serum levels of thrombopoietin in health and disease. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, editors. Thrombopoiesis and thrombopoietins: molecular, cellular, preclinical, and clinical biology. Totowa, NJ: Humana Press. pp. 359-375.
32. Nichol JL. Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention. Stem Cells 1998; 16 (Suppl 2):165-175.
33. Aledort LM, Hayward CP, Chen MG, et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76:205-213.
34. Kuwana M, Okazaki Y, Satoh T, et al. Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. Am J Med 2005; 118:1026-1033. (Pubitemid 41297768)
35. George JN, Terrell TR. Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica 2008; 93:1445-1449. A review of the different classes of thrombopoietic agents and the rationale for treatment.
36. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276:1696-1699. (Pubitemid 27421976)
37. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628-638. (Pubitemid 39601552)
38. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672-1681. (Pubitemid 44583957)
39. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose- finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135:547-553. (Pubitemid 44583422)
40. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395-403. A report on the largest study so far in patients before and after splenectomy using the subcutaneous product romiplostim.
41. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113:2161-2171. Follow-up to 3 years in patients on long-term romiplostim reviewing the safety and efficacy profile.
42. Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007; 139:351-362. (Pubitemid 47512180)
43. Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem 2001; 44:3730-3745. (Pubitemid 33026681)
44. Luengo JI, Duffy KJ, Shaw AN, et al. Discovery of SB-497115, a smallmolecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. ASH Annu Meet Abstr 2004; 104:2910.
45. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005; 33:85-93. (Pubitemid 40127647)
46. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739-4741. (Pubitemid 46827766)
47. Bussel JB, Cheng G, Saleh M, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237-2247. (Pubitemid 350190754)
48. Bussel JB, Provan A, Shamsi T, et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study. In: Proceedings of the 12th Congress of the European Hematology Association; 7-10 June 2007; Vienna, Austria; abstract 0390.
49. Bussel JB, Cheng G, Kovaleva L, et al. Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): preliminary data from the EXTEND study. Blood (ASH Annu Meet Abstr) 2007; 110:566.
50. Kantarjian HM, Fenaux P, Sekeres MA, et al. Phase I/II study of ROMIPLOSTIM in thrombocytopenic patients with low risk myelodysplastic syndrome: update including extended treatment [abstract]. Blood 2007; 110:81a.
51. McMillan R, Bussel JB, George JN, et al. Self-reported health related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008; 83:150-154. A study showing that patients with ITP are often significantly more compromised in normal daily function than many comparable patients with chronic disease.
52. George JN, Mathias SD, Go SN, et al. Improved quality of life for romiplostimtreated patients with chronic immune thrombocytopenic purpura: results of two randomized, placebo-controlled trials. Br J Haematol 2008; 144:409-415. An important study using the relatively new patient assessment questionnaire assessing the improvement over placebo in a number of activity measures.